AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioNTech, Pfizer Receive EMA Recommendation for COVID-19 Vaccine Approval
ByAinvest
Friday, Jul 25, 2025 11:39 am ET1min read
BioNTech SE and Pfizer Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1) for individuals 6 months of age and older. The vaccine is designed to prevent COVID-19 caused by SARS-CoV-2. The companies are developing a COVID-19 vaccine, the BNT162b2 mRNA vaccine program, and the Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2).
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Pfizer Inc. (PFE) and BioNTech SE (BNTX)'s LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY LP.8.1, for individuals aged 6 months and older [1]. The recommendation is based on the EMA's Emergency Task Force (ETF) recommendation to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season.The LP.8.1-adapted vaccine has shown improved immune responses against currently dominant and emerging SARS-CoV-2 lineages compared to the 2024-2025 vaccine formulations [2]. This adaptation aims to maintain the effectiveness of the vaccines as the virus continues to evolve.
The CHMP's recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the LP.8.1-adapted vaccine to ensure supply readiness ahead of the upcoming fall and winter season [3].
The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and have demonstrated a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance, and manufacturing data [3].
References:
[1] https://www.rttnews.com/3557477/pfizer-biontech-receive-positive-chmp-opinion-for-lp-8-1-adapted-covid-19-vaccine.aspx
[2] https://seekingalpha.com/news/4472112-pfizer-biontech-win-eu-backing-new-covid-shot
[3] https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-lp81-adapted-0?mobile=1
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet